These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 8610061)
1. Effect of aromatase inhibitor, TZA-2209, on the prostate of androstenedione-treated castrated dogs: changes in prostate volume and histopathological findings. Suzuki K; Ito K; Tamura Y; Suzuki T; Honma S; Yamanaka H Prostate; 1996 May; 28(5):328-37. PubMed ID: 8610061 [TBL] [Abstract][Full Text] [Related]
2. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia. Ito K; Fukabori Y; Shibata Y; Suzuki K; Mieda M; Gotanda K; Honma S; Yamanaka H Eur J Endocrinol; 2000 Oct; 143(4):543-54. PubMed ID: 11022202 [TBL] [Abstract][Full Text] [Related]
3. Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results. Habenicht UF; Schwarz K; Schweikert HU; Neumann F; el Etreby MF Prostate; 1986; 8(2):181-94. PubMed ID: 2419882 [TBL] [Abstract][Full Text] [Related]
4. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia. el Etreby MF; Nishino Y; Habenicht UF; Henderson D J Androl; 1991; 12(6):403-14. PubMed ID: 1722797 [TBL] [Abstract][Full Text] [Related]
5. Effects of long-term administration of androgens and estrogen on rhesus monkey prostate: possible induction of benign prostatic hyperplasia. Jeyaraj DA; Udayakumar TS; Rajalakshmi M; Pal PC; Sharma RS J Androl; 2000; 21(6):833-41. PubMed ID: 11105909 [TBL] [Abstract][Full Text] [Related]
6. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies. Habenicht UF; el Etreby MF J Androl; 1991; 12(6):395-402. PubMed ID: 1722796 [TBL] [Abstract][Full Text] [Related]
7. Synergic inhibitory effects of the aromatase inhibitor 1-methyl-androsta-1, 4-diene-3, 17-dione and the antiandrogen cyproterone acetate on androstenedione-induced hyperplastic effects in the prostates of castrated dogs. Habenicht UF; el Etreby MF Prostate; 1987; 11(2):133-43. PubMed ID: 2444953 [TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of androstenedione-induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione (1-methyl-ADD). Habenicht UF; el Etreby MF Prostate; 1989; 14(4):309-22. PubMed ID: 2473459 [TBL] [Abstract][Full Text] [Related]
9. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. Ho CK; Nanda J; Chapman KE; Habib FK J Endocrinol; 2008 Jun; 197(3):483-91. PubMed ID: 18492814 [TBL] [Abstract][Full Text] [Related]
10. The function and the role of aromatase inhibitors in the treatment of BPH. el Etreby MF; Habenicht UF Prog Clin Biol Res; 1994; 386():209-30. PubMed ID: 7528389 [No Abstract] [Full Text] [Related]
11. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma. Leav I; Schelling KH; Adams JY; Merk FB; Alroy J Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344 [TBL] [Abstract][Full Text] [Related]
12. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma. Leav I; Schelling KH; Adams JY; Merk FB; Alroy J Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the effect of the aromatase inhibitor, anastrazole, to the antioestrogen, tamoxifen citrate, on canine prostate and semen. Gonzalez G; Guendulain C; Maffrand C; Gobello C Reprod Domest Anim; 2009 Jul; 44 Suppl 2():316-9. PubMed ID: 19754594 [TBL] [Abstract][Full Text] [Related]
14. Effect of antiandrogen, chlormadinone acetate (CMA), in canine spontaneous benign prostatic hyperplasia (BPH). Murakoshi M; Ikada R; Tagawa M; Nakayama T Tokai J Exp Clin Med; 2000 Apr; 25(1):11-4. PubMed ID: 11023050 [TBL] [Abstract][Full Text] [Related]
15. Androgen and prostatic stroma. Niu YJ; Ma TX; Zhang J; Xu Y; Han RF; Sun G Asian J Androl; 2003 Mar; 5(1):19-26. PubMed ID: 12646998 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat. Silva J; Pinto R; Carvallho T; Coelho A; Avelino A; Dinis P; Cruz F Eur Urol; 2009 Jul; 56(1):134-40. PubMed ID: 18649990 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of chlormadinone acetate-pellet implantation and orchidectomy on benign prostatic hypertrophy in the dog. Kawakami E; Tsutsui T; Shimizu M; Orima H; Fujita M; Ogasa A Int J Androl; 1995 Oct; 18(5):248-55. PubMed ID: 8567095 [TBL] [Abstract][Full Text] [Related]
18. Metabolism of androgens in human benign prostatic hyperplasia: aromatase and its inhibition. Bartsch W; Klein H; Stürenburg HJ; Voigt KD J Steroid Biochem; 1987; 27(1-3):557-64. PubMed ID: 2447391 [TBL] [Abstract][Full Text] [Related]
19. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703 [TBL] [Abstract][Full Text] [Related]
20. Anti-androgenic action by red clover-derived dietary isoflavones reduces non-malignant prostate enlargement in aromatase knockout (ArKo) mice. Jarred RA; McPherson SJ; Jones ME; Simpson ER; Risbridger GP Prostate; 2003 Jun; 56(1):54-64. PubMed ID: 12746847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]